Ascendis_FINAL_LOGO_7.23.15.png
Ascendis Pharma A/S Announces Two Oral Presentations Highlighting the Potential for TransCon™ PTH to be a Replacement Therapy for Adult Hypoparathyroidism at ENDO 2022
June 07, 2022 08:00 ET | Ascendis Pharma
–  Late-breaker oral presentation of TransCon PTH Phase 3 PaTHway Trial data in adult hypoparathyroidism on Tuesday, June 14 –  Oral presentation of TransCon PTH Phase 2 PaTH Forward Trial Open-Label...
Ascendis_FINAL_LOGO_7.23.15.png
Positive Results from VISEN’s Phase 3 Trial of Once-Weekly TransCon hGH in China Consistent with Ascendis Pharma’s Phase 3 Height Trial
May 23, 2022 08:00 ET | Ascendis Pharma
-   VISEN’s Phase 3 Trial achieved primary endpoint; pediatric growth hormone deficiency (GHD) patients treated with TransCon™ hGH demonstrated greater annualized height velocity at 52-weeks...
Ascendis_FINAL_LOGO_7.23.15.png
Ascendis Pharma A/S Announces New Commercial Endocrinology Leadership Appointments
May 23, 2022 08:00 ET | Ascendis Pharma
-  Joe Kelly has been appointed to the newly created role of Head of U.S. Commercial, Endocrinology -  Scott A. Holmes has been appointed to the newly created role of Head of Global Commercial...
Ascendis_FINAL_LOGO_7.23.15.png
Ascendis Pharma A/S Reports First Quarter 2022 Financial Results
May 11, 2022 16:01 ET | Ascendis Pharma
Phase 3 PaTHway Trial top-line results demonstrated potential of TransCon™ PTH to become the first parathyroid replacement therapy for adults with hypoparathyroidismTransCon PTH U.S. FDA regulatory...
Ascendis_FINAL_LOGO_7.23.15.png
Ascendis Pharma A/S to Participate in the BofA Securities 2022 Healthcare Conference
May 09, 2022 08:00 ET | Ascendis Pharma
COPENHAGEN, Denmark, May 09, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) announced today that the company is scheduled to attend the BofA Securities 2022 Healthcare Conference....
Ascendis_FINAL_LOGO_7.23.15.png
Ascendis Pharma A/S Announces First Quarter 2022 Financial Results and Business Update Conference Call on May 11
May 04, 2022 16:05 ET | Ascendis Pharma
COPENHAGEN, Denmark, May 04, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) announced today that the company will hold a conference call and live webcast on Wednesday, May 11, 2022 at...
Ascendis_FINAL_LOGO_7.23.15.png
Ascendis Pharma A/S to Present New Endocrinology Results at Four Medical Meetings in May
May 01, 2022 07:00 ET | Ascendis Pharma
New data highlights include: - Phase 3 open-label extension study data for growth hormone-deficient children treated for 2.5 years with TransConTM hGH - Initial findings from...
Ascendis_FINAL_LOGO_7.23.15.png
Ascendis Pharma Prices US$500.0 Million Convertible Senior Notes Offering
March 24, 2022 22:41 ET | Ascendis Pharma
COPENHAGEN, Denmark, March 24, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to create new product...
Ascendis_FINAL_LOGO_7.23.15.png
Ascendis Pharma Announces Proposed Convertible Senior Notes Offering
March 23, 2022 16:01 ET | Ascendis Pharma
COPENHAGEN, Denmark, March 23, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to create new product...
Ascendis_FINAL_LOGO_7.23.15.png
Ascendis Pharma A/S Announces Phase 3 PaTHway Trial of TransCon™ PTH in Adults with Hypoparathyroidism Met Primary and All Key Secondary Endpoints
March 13, 2022 17:53 ET | Ascendis Pharma
–  For the primary composite endpoint, TransCon PTH demonstrated a response rate of 78.7% compared to 4.8% for control (p-value <0.0001). –  TransCon PTH demonstrated statistically significant...